January 21, 2011
Both, Biogen-Acorda’s Fampyra, click here to review related stories
and Merck’s MS Oral Pill, click here for available stories,
were both rejected earlier this week.
Both, Biogen-Acorda’s Fampyra, click here to review related stories
and Merck’s MS Oral Pill, click here for available stories,
were both rejected earlier this week.
“Providing You with ‘MS Views and News’, is what we do“
.
REMAIN up–to–date with educational information of
Multiple Sclerosis when registered at
the MS Views and News website.
.
****************************************************************
Disclaimer: ‘MS Views and News’ (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
. ****************************************************************
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews